For millions of women worldwide, the journey toward breast reconstruction following a mastectomy is a pivotal step in recovery and healing. A cornerstone of this process is the placement of tissue expanders—a surgical technique designed to stretch the skin and create a pocket for a future permanent implant. However, a significant and persistent hurdle in this procedure is the incidence of surgical site infections (SSIs).
A landmark study published in the February issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS), has shed light on a counterintuitive risk factor for these infections: the recent use of antibiotics. According to the research, patients who took antibiotics within 30 days prior to their reconstructive surgery faced a four-fold increase in the risk of developing a postoperative infection.
Main Facts: A Counterintuitive Correlation
The study, conducted by a team of researchers led by Bernard T. Lee, MD, MBA, MPH, of Beth Israel Deaconess Medical Center and Harvard Medical School, challenges the traditional assumption that antibiotic use is a universal protective measure. Instead, the data suggests that for women undergoing tissue expander-based breast reconstruction, recent exposure to antibiotics may paradoxically set the stage for complications.
"In our study, patients who took antibiotics within 30 days before surgery to place tissue expanders had a four-fold increase in SSI risk—possibly due to disruption of the normal balance of protective versus pathogenic bacteria," Dr. Lee explained.
The core of the issue lies in the concept of "dysbiosis"—a state where the body’s microbiome, the complex community of microorganisms living in and on the human body, is thrown out of balance. While antibiotics are designed to kill harmful bacteria, they are non-selective; they often decimate the beneficial "good" bacteria that help prevent the overgrowth of more dangerous, pathogenic, or antibiotic-resistant strains. When this delicate equilibrium is disrupted, the patient may become more susceptible to infections when the skin is incised and a foreign device—the tissue expander—is introduced into the body.
Chronology: The Methodology of the Investigation
To reach these conclusions, the researchers performed a robust, large-scale retrospective analysis. Utilizing an extensive research database, the team identified two distinct cohorts of patients who had undergone tissue expander-based breast reconstruction.
- The Exposed Group: This group consisted of 1,383 patients who had received a prescription for antibiotics within the 30-day window preceding their surgical procedure.
- The Control Group: This group comprised 1,383 patients who had not taken antibiotics during that same 30-day period.
To ensure the integrity of the comparison, the researchers utilized propensity score matching. This statistical technique allowed them to pair patients from each group based on shared risk factors known to influence infection rates, such as body mass index (obesity), smoking status, age, and the clinical stage of their breast cancer. By balancing these variables, the researchers were able to isolate the impact of the antibiotic exposure itself, effectively stripping away other potential confounding factors.
The tracking period for these patients extended beyond the immediate surgery. The team monitored outcomes at 30 days, with follow-up assessments continuing through 60 and 90 days post-operation to observe the long-term impact of the pre-surgical antibiotic exposure on wound healing and device retention.
Supporting Data: Quantifying the Risk
The findings of the study are statistically significant and provide a stark warning regarding the preoperative use of antibiotics. The relative risk (RR) of developing a surgical site infection within the first 30 days after the procedure was calculated at 3.91 for the exposed group compared to the control group. In simpler terms, the risk of infection was nearly four times higher for those who had taken antibiotics recently.
Beyond the raw incidence of infection, the data revealed a cascading effect on patient outcomes:
- Wound Healing Complications: Patients in the exposed group were approximately twice as likely to experience wound dehiscence—a complication where the surgical incision fails to close properly or pulls apart.
- Device Removal: Due to persistent infection or complications, patients in the exposed group were also twice as likely to require the surgical removal of the tissue expander, a devastating setback in the reconstruction process that necessitates further surgeries and delays.
- Post-Operative Antibiotic Use: Perhaps indicating that the initial infections were more difficult to treat, those in the exposed group were more likely to be prescribed additional antibiotics following the surgery.
While the elevated risk began to taper off during the 60- to 90-day follow-up windows, it remained notably higher than in the control group. This prolonged vulnerability suggests that the "dysbiosis" caused by antibiotics is not an immediate, transient issue, but one that requires a significant period of time—likely months—for the body’s natural microbiome to fully recover and regain its protective capacity.
Official Responses and Perspectives
Dr. Bernard T. Lee and his co-authors emphasized that these findings carry weight for the entire field of plastic and reconstructive surgery. "For plastic surgeons, the findings suggest the need for careful assessment of antibiotic use in patients undergoing tissue expander-based breast reconstruction," Dr. Lee stated.
The medical community has long recognized that antibiotic resistance is a growing global crisis, but this study provides a specific, surgical-contextual reason for caution. The authors note that the study has limitations, primarily that the database did not specify why the patients were prescribed antibiotics before their surgery (e.g., for a urinary tract infection, a respiratory issue, or a dental procedure). However, the strength of the correlation is sufficient to warrant a shift in how surgeons evaluate a patient’s preoperative health.
The researchers are calling for randomized clinical trials to move beyond observation and confirm the causal link between preoperative antibiotic use and surgical infection. Furthermore, they suggest that future research should investigate potential mitigations. For example, if a patient must take antibiotics for a systemic infection prior to breast reconstruction, could the use of targeted probiotics help restore the microbiome and mitigate the surgical risk? This represents a new frontier in "perioperative optimization"—preparing the patient’s biological state as thoroughly as their physical state.
Implications for Clinical Practice
While the authors are careful to state that these findings do not necessitate an immediate, universal change to clinical practice, they do provide a crucial new piece of information for the preoperative checklist.
1. Informed Consent and Patient History
Surgeons should now place increased emphasis on detailed medication histories during the 30 days leading up to surgery. If a patient has recently completed a course of antibiotics, the surgeon may need to counsel the patient on the potential for increased risk, potentially even discussing the feasibility of delaying the surgery until the patient’s microbiome has had more time to stabilize.
2. Broadening the Scope
While the current study focused specifically on tissue expander-based breast reconstruction, the implications likely extend to other surgical fields. Any procedure that involves the placement of a permanent or temporary foreign body—such as joint replacements, cardiac implants, or other aesthetic surgeries—could theoretically be subject to the same microbiome-related risks. The study serves as a catalyst for a broader investigation into how systemic antibiotic use affects localized surgical outcomes.
3. A Shift in Perspective on "Prophylaxis"
There is a long-standing tradition in medicine of "better safe than sorry," which often leads to the overuse of antibiotics. This study suggests that, in the context of breast reconstruction, that philosophy may be causing more harm than good. By potentially encouraging the overgrowth of opportunistic, resistant bacteria, preemptive antibiotic use might be inadvertently creating the very infections it seeks to prevent.
Conclusion: The Path Forward
The study published in Plastic and Reconstructive Surgery represents a significant evolution in our understanding of surgical safety. By highlighting the potential detrimental consequences of preoperative antibiotic use, Dr. Lee and his colleagues have provided a compelling argument for a more nuanced approach to patient care.
As medicine continues to move toward more personalized and data-driven treatments, the microbiome is emerging as a critical, yet often overlooked, component of surgical success. For the thousands of women undergoing breast reconstruction annually, this research offers a pathway to safer outcomes, fewer complications, and a smoother road to recovery. As clinical trials continue to investigate these associations, the medical community must remain vigilant, balancing the benefits of antibiotic therapy against the complex, and sometimes harmful, ecological impact these drugs have on the human body.
Reference:
Recent Antibiotic Use and Surgical Site Infections in Tissue Expander–Based Breast Reconstruction: A Propensity Score–Matched Analysis. (doi: 10.1097/PRS.0000000000012333). Published in Plastic and Reconstructive Surgery.
About Wolters Kluwer:
Wolters Kluwer (EURONEXT: WKL) is a global leader in professional information, software solutions, and services for the healthcare, tax and accounting, financial and corporate compliance, legal and regulatory, and corporate performance and ESG sectors. The company is dedicated to helping customers make critical, evidence-based decisions through deep domain knowledge and specialized technology.
About the Author
